QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant a...

Full description

Saved in:
Bibliographic Details
Main Authors BARBOUR, PATRICK MICHAEL, TARLTON, EUGENE, BROWN, KATIE KEATON, KAHN, DEAN RUSSELL, PRIGARO, BRETT JOSEPH, REN, LI, HICKEN, ERIK JAMES, MORENO, DAVID AUSTIN, NEWHOUSE, BRADLEY JON, METCALF, ANDREW TERRANCE, PAJK, SPENCER PHILLIP, LAIRD, ELLEN RUTH, COOK, ADAM WADE
Format Patent
LanguageEnglish
French
Published 12.09.2023
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors. L'invention concerne des composés de Formule I : et des sels, solvats et polymorphes pharmaceutiquement acceptables de ceux-ci, dans laquelle L, X1, R1, R2, R3, R4, R5 et R6 sont tels que définis dans la description, pour le traitement de maladies et de troubles associés à BRAF, notamment des tumeurs associées à BRAF, comprenant des tumeurs malignes et bénignes du SNC associées à BRAF et des tumeurs malignes extracraniennes associées à BRAF.
Bibliography:Application Number: CA20203144859